AstraZeneca-BMS Merger Talks Draw 'Odd' Verdict From Analysts
Get the Finance newsletter
Daily finance — markets, central banks, M&A, the prints that move money. Free.
- AstraZeneca and Bristol Myers Squibb are in early-stage merger talks first reported Sunday by the Financial Times, and a tie-up could create 'an oncology powerhouse' spanning immuno-oncology, targeted therapies, antibody-drug conjugates, and hematology oncology, according to RBC Capital Markets analyst Trung Huynh.
- AstraZeneca shares closed down 6.9% on Monday while Bristol Myers Squibb was essentially flat, a split Bank of America's Sachin Jain flagged by calling the combination 'odd' and warning it may signal 'a lack of confidence in [AZN's] pipeline' — fresh off a rare late-stage failure of heart drug Wainua in ATTR-CM patients last month.
- Cancer drugs made up 44% of AstraZeneca's 2025 revenue and roughly half of Bristol Myers' sales, and RBC expects the combined oncology scale to draw 'lengthy review and possible divestitures' from U.S. and U.K. antitrust regulators.
- Bristol Myers carries near-term catalysts including readouts for idiopathic pulmonary fibrosis drug admilparant, blood-clot drug milvexian, and Cobenfy in Alzheimer's psychosis — a cluster that makes the timing of deal talks puzzling for a company already facing major market-moving news, per BofA.
- Bristol Myers trades at roughly 10x 2027 estimated earnings versus AstraZeneca's 14x per FactSet, but Jefferies said it was 'perplexed,' noting BMY is cheap 'for a reason' given upcoming patent expirations and that AstraZeneca 'doesn't need financial engineering.'
Why it matters: For AstraZeneca holders, the 6.9% Monday selloff on reported merger talks reflects a market read — shared by BofA — that AZN, already down 7% year-to-date and still digesting its Wainua ATTR-CM failure, is the party being pushed into a defensive deal. Cambridge-based AZN's U.K. listing status and BMS's New York base ensure that any completed tie-up would face a rare two-jurisdiction antitrust review.
Ask SkimNews
